6 Followers iHub
1,091 Followers StockTwits (Only ~40 new followers in three weeks)
4,475 Followers SeekingAlpha (Their board is also inactive)
You said you are in $INO
596 Followers iHub
46,075 Followers StockTwits
43,563 Followers SeekingAlpha
Anything over $7, the chatter will be somewhere else. Especially if its not a OTC stock.
But, $ARCT is very promising for an ultra vaccine solution to the world.
Did you catch that they sold 2MM shares at $10/share to two investment firms as an additional capital raise. Listen to their last call on SeekingAlpha if you haven't already.
To me, than means if those firms did their homework, then they are looking for 10x return.
That means $ARCT which is at $17 will go to over +$100 if they can pull it off.
Not only are they working for vaccine solution, but they are doing it in a way that will scale production to supply the world, quick.
Think of the volume in the syringe of your last flu shot and then with $ARCT solution you would only need 1/100 the dose. I think its actually less - 1/1000?
Been buying since it was at $12
Sure would be nice to have 1MM shares of $ARCT
" faber est suae quisque fortunae " The above is for informational purposes only, responsibility for all trading decisions lies solely with the reader.
Recent ARCT News
- Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma • PR Newswire (US) • 09/13/2024 12:15:00 PM
- Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma • Business Wire • 09/13/2024 12:00:00 PM
- Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis • Business Wire • 09/03/2024 12:30:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 08/27/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:54:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:50:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:09:24 PM
- Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress • Business Wire • 08/05/2024 08:01:00 PM
- Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference • Business Wire • 08/01/2024 08:01:00 PM
- Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 • Business Wire • 07/18/2024 11:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/17/2024 09:27:11 PM
- Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs • Business Wire • 07/01/2024 08:01:00 PM
- Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors • Business Wire • 06/20/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:01:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:00:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:36 PM
- Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference • Business Wire • 06/07/2024 02:30:00 PM
- Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program • Business Wire • 05/28/2024 10:30:00 AM
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine • Business Wire • 05/20/2024 12:30:00 PM
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine • PR Newswire (US) • 05/20/2024 12:30:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 05/15/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:17:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:04 PM
- Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress • Business Wire • 05/08/2024 08:01:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM